Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guérin immunotherapy: a systematic review and meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated neutrophil-to-lymphocyte ratio (NLR) predicts recurrence and progression in non-muscle-invasive bladder cancer (NMIBC) patients receiving Bacillus Calmette-Guérin (BCG) immunotherapy after TURBT. This finding aids in predicting patient outcomes.
Area Of Science
- Urology
- Oncology
- Immunotherapy
Background
- Non-muscle-invasive bladder cancer (NMIBC) requires effective prognostic markers.
- Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is a standard treatment for NMIBC.
- Predictive accuracy of preoperative neutrophil-to-lymphocyte ratio (NLR) for NMIBC prognosis with BCG immunotherapy is unclear.
Conclusions
- Preoperative NLR is a significant predictor of recurrence in NMIBC patients treated with BCG immunotherapy.
- Elevated NLR levels are associated with a higher risk of disease progression post-TURBT and BCG.
- NLR can serve as a valuable prognostic biomarker for NMIBC patients undergoing BCG immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.